How to Prevent Prostate Cancer: What Works, What Doesn't, and What Matters More
Most men want a simple answer to this question. The honest answer takes a few minutes, but it is worth your time, because the simple answers being sold are mostly wrong.
Let's start with the gland itself.
What the prostate is and what it does
The prostate is a small gland that sits below the bladder in men. It is roughly the size of a walnut in a young man, and it grows larger with age.
The urethra, the tube that carries urine out of the body, runs right through the middle of it. That is why prostate problems so often show up as trouble urinating.
Its main job is making fluid. That fluid mixes with sperm to make semen.
Why testosterone matters here
The prostate depends on male hormones to work.
Testosterone travels through your blood. When it reaches the prostate, an enzyme called 5-alpha reductase changes it into a stronger hormone called DHT. An enzyme is simply a protein that speeds up a chemical change in the body.
DHT tells prostate cells to grow. This is normal and necessary.
Because of this, the two most studied prevention drugs, finasteride and dutasteride, both work by blocking that conversion. Researchers have also tested other approaches, including vitamins, minerals, anti-inflammatory drugs, and diet changes. Most either failed or gave uncertain results. We will come back to the two drugs later, because their story is more complicated than either their fans or their critics admit.
One thing worth knowing up front: having normal testosterone or DHT levels has not been shown to cause prostate cancer. The hormone pathway matters for how the gland works, not as something to fear in your own bloodwork.
Prostate cancer does not all behave the same way
This is the part most articles skip, and it changes everything.
Prostate cancer is not one disease. It sits on a range.
At one end sit low-risk cancers, and they are extremely common. As men age, small cancers form in the prostate. We know this because researchers have examined the prostates of men who died of other causes. About 1 in 20 men under 30 already have one. By ages 60 to 69, roughly 1 in 3 do. Past age 79, close to 6 in 10 do.
Most of these men never knew. Many of these cancers grow so slowly that they never cause a symptom and never shorten a life. Plenty of men die in old age of something else with one still sitting quietly in the gland.
That does not make prostate cancer a normal part of aging. It means many prostate cancers stay silent for life.
At the other end sit high-risk cancers. These are more likely to grow beyond the gland and spread, often to the bones, and to cause death if treatment does not succeed. These are the cancers it matters most to find and treat.
And plenty of cancers land in the middle. Doctors sort them into low, intermediate, and high risk, and the middle group is genuinely uncertain. Some stay quiet. Some do not.
Doctors are not flying blind here. They can estimate how likely a cancer is to progress using its grade, how far it has spread, PSA results, imaging, and in some cases genetic tests on the tumor itself. What no test can do is tell you what one particular cancer will do over the next twenty years.
Now here is why the range matters. When someone says "prevent prostate cancer," they almost never say which part of the range they mean. Cutting down diagnoses of cancers that were never going to cause symptoms is unlikely to save any lives. Cutting down the cancers that spread and kill would save lives, and no one has found a dependable way to do that.
So the useful question is not "how do I avoid getting prostate cancer." It is "how do I avoid dying of it."
Why this matters more right now
For years, prostate cancer deaths in the United States fell rapidly. That progress has slowed sharply.
The American Cancer Society reported in 2025 that new cases had reversed direction. They fell by 6.4 percent a year from 2007 to 2014. Since 2014 they have climbed by 3.0 percent a year. The steepest rise is in advanced-stage disease, up 4.6 to 4.8 percent per year, and it is rising in men of every age. Meanwhile the drop in death rates slowed from 3 or 4 percent a year in the 1990s and 2000s to 0.6 percent a year over the past decade.
Deaths are still falling. They are just falling much more slowly, while more men turn up with cancer that has already spread.
What you cannot change, and why you still need to know it
A few things raise your risk more than anything on any diet list. You cannot change them. You can still act on them.
Age. Risk climbs steeply after 50.
Ancestry. Black men are diagnosed at rates 67 percent higher than White men. More importantly, they are about twice as likely to die of prostate cancer.
Family history. If your father or brother had prostate cancer, your risk roughly doubles. It matters more if he was diagnosed young.
Inherited gene changes. Some families carry an inherited gene change that raises cancer risk. Doctors call these pathogenic variants. The best studied is BRCA2, one of the genes also linked to breast and ovarian cancer, and the evidence for BRCA2 is stronger than for BRCA1. Other genes matter too, including HOXB13, the genes behind Lynch syndrome, and genes involved in repairing DNA such as ATM and CHEK2.
What raises the suspicion of an inherited syndrome is a pattern, not a single case. Look for prostate, breast, ovarian, pancreatic, colon, or uterine cancers appearing in several relatives, or appearing unusually young. One ordinary late-life cancer in one relative is not the same signal.
If you see that pattern on either side of your family, ask your doctor about genetic counseling. A genetic counselor helps you decide whether testing makes sense. A BRCA2 result can justify starting the screening conversation earlier and following up more closely, though there is no single agreed schedule.
These are the best-established risk factors we have. Everything on the diet-and-lifestyle list has shown weaker and less consistent links.
What does not work
Vitamin E and selenium. A study called SELECT gave more than 35,000 men vitamin E, selenium, both, or a dummy pill. Nobody knew which pill they got.
In 2008 the independent committee watching the study told the men to stop taking their supplements. The reason was that neither supplement was preventing prostate cancer. At that point there were two worrying trends, slightly more prostate cancer in the vitamin E group and a slightly higher number of diabetes diagnoses in the selenium group, but neither difference was large enough to rule out chance.
Then the follow-up data came in. With more time, the vitamin E finding became clear and significant. Men taking 400 IU of vitamin E daily had about 17 percent more prostate cancer than men on the dummy pill. The diabetes signal in the selenium group never firmed up and did not hold. Later analyses raised questions about high-grade cancer in men who started the trial with particular selenium levels, but that was a subgroup finding, not a result across everyone taking selenium.
What SELECT established is narrower than the headlines suggested, and still worth acting on. High-dose vitamin E does not prevent prostate cancer and appears to raise the risk of getting it. Selenium does not prevent it either.
One caution about how to read this. SELECT tested particular doses and particular formulations in a particular group of men. It does not prove that the small amounts in an ordinary multivitamin are harmful. It does mean there is no reason to take either supplement hoping to protect your prostate.
Beta-carotene does not help either. It has been tested and it does not lower risk.
What might help
Do not smoke. This is the clearest item on the list, and it follows the same strange pattern you are about to see with body weight.
Smokers are diagnosed with prostate cancer slightly less often than non-smokers. But when researchers pooled prospective studies, current smokers had roughly a 24 percent higher risk of dying of prostate cancer, and the risk climbed with the number of cigarettes smoked per day. Other pooled analyses have put the figure higher. The U.S. Surgeon General grades the evidence that smoking raises prostate cancer death rates as probable.
Fewer diagnoses, more deaths. That combination tells you the diagnoses were never the thing to measure.
Keep a healthy weight, and watch your waist. Here the evidence is observational, meaning researchers watched what happened to men rather than randomly assigning them to gain or lose weight. That distinction matters, and it is why nobody can promise you an outcome.
Heavier men are also diagnosed with prostate cancer slightly less often. Part of the reason involves the PSA blood test, which measures a protein made by the prostate. Men carrying more weight have more blood volume. The same amount of PSA spread through more blood produces a lower reading. That can make PSA results harder to read in heavier men, and it may contribute to cancer being found later.
But testing effects do not appear to explain everything. In a trial called REDUCE, men received biopsies on a fixed schedule rather than only when their PSA looked high. That reduced the chance that lower PSA readings alone explained the pattern. Obesity still went along with more high-grade cancer and less low-grade cancer.
Other studies link excess body fat, and deep belly fat in particular, to advanced and fatal prostate cancer. One study used scans to measure where fat actually sat on the body and found deep belly fat tracked with worse outcomes.
Why might body fat do this? Researchers have proposed several explanations, including long-term low-level inflammation, changes in insulin signaling, and chemical signals released by fat tissue. These are working theories, not settled answers.
So here is the fair summary. Carrying less excess fat is good for you for many well-proven reasons, and it may go along with a lower risk of the dangerous kind of prostate cancer. No trial has shown that losing belly fat prevents lethal prostate cancer.
Exercise regularly. The case for exercise rests on your heart, your metabolism, your bones, and your overall health, where the evidence is strong. Whether it specifically prevents advanced prostate cancer is still unsettled.
Eat well, but do not treat food as medicine. A diet built on vegetables, fruit, whole grains, and fish, with less red and processed meat, is good for you for many reasons. Whether it prevents prostate cancer specifically is far less certain than most articles suggest.
Tomatoes show why you should be careful. Tomatoes contain lycopene, the pigment that makes them red, and lycopene was promoted for years as prostate protection. Then in 2014 the World Cancer Research Fund, which reviews all the studies together, looked again and downgraded it. They had previously called the evidence strong. After review, they concluded no conclusion was possible.
A Spanish study published in 2025 found men eating the most lycopene had 54 percent lower risk. It came out after that 2014 review and so was not part of it. Read it carefully in the meantime. It followed about 3,000 older men already at high risk of heart disease, for under six years, and counted only 104 cancers. With that few cases the estimate is imprecise. And because the researchers observed men rather than assigning them to eat more lycopene, other differences between the high-lycopene and low-lycopene groups could explain part or all of what they saw.
Eat tomatoes. They are good food. Do not measure them out like a prescription, and do not skip a screening conversation because you had marinara last night.
Go easy on very high calcium. Some observational studies link very high calcium intake to modestly higher prostate cancer risk. The World Cancer Research Fund also downgraded this one in 2014, from strong evidence to limited, so treat it as unsettled. Get enough calcium for your bones. Do not take large amounts well above the recommended level without a medical reason.
What about the prostate drugs?
Finasteride and dutasteride block the 5-alpha reductase enzyme described earlier. Less DHT means a weaker growth signal to prostate cells.
They reduce diagnoses. In a large trial, seven years of finasteride dropped prostate cancer diagnoses from about 24 men in every 100 to about 18 in every 100.
That trial also found more high-grade cancer in the finasteride group, which alarmed doctors for years and led the FDA to advise against using it for prevention. Later work suggests much of that finding came from measurement effects rather than real harm. The drug shrinks the gland, so a biopsy needle samples a larger share of it, and PSA readings behave differently. That likely improved detection. It is a strong explanation, but it does not prove that every extra high-grade tumor was simply one that would otherwise have been missed.
Longer follow-up brought more reassurance on the mortality question without answering it. After about 18 years, prostate cancer deaths were 0.43 percent in the finasteride group and 0.60 percent in the placebo group. That difference points in finasteride's favor, but it was not statistically significant, meaning it could have come about by chance. So the trial did not show that finasteride reduces prostate cancer deaths, and it produced no evidence that the drug increases them. Its clearest effect was reducing diagnoses of lower-grade disease.
One practical point if you take either drug for any reason: they lower your PSA reading. Your doctor needs to know you are taking one in order to interpret your PSA correctly.
What has the strongest evidence behind it
If your goal is not dying of prostate cancer, the approach with actual randomized-trial evidence behind it is not prevention. It is finding the serious cancers while they are still contained in the gland, when a cure is still possible.
A large European study followed more than 162,000 men aged 55 to 69 for up to 23 years. About 73,000 were invited for repeated PSA testing and about 89,000 were not.
The men invited for screening were 13 percent less likely to die of prostate cancer. Put in absolute terms, the difference in death rates between the two groups was about 0.22 percentage points. Roughly 456 men had to be invited, and about 12 extra cancers had to be diagnosed, to prevent one prostate cancer death.
That last figure is a population number, not a personal one. It does not mean one man in every 12 diagnosed was personally saved.
That is a real benefit and a modest one. It also improves with time. At 16 years it took 628 invitations to prevent one death. By 23 years it took 456. The benefit builds slowly, while the downsides arrive immediately.
You should also know about the large American trial, called PLCO, which found no reduction in prostate cancer deaths from organized yearly screening. There were 255 prostate cancer deaths in the screened group and 244 in the comparison group after a median of 15 years.
The catch is what the comparison group actually did. About 86 percent of them got PSA testing anyway, outside the study. So the trial ended up comparing organized screening against informal screening, rather than screening against none at all. That is how the researchers themselves describe it. The two trials answered different practical questions, and an honest account includes both.
The honest downside, and how it got better
Screening has a real problem, and you should hear it before deciding.
The root of it is this: PSA screening can find cancers that would never have caused symptoms or shortened a man's life. Once found, they often get treated. Treatment can cause lasting incontinence and erectile problems. So screening can take a man who would have lived a normal life and hand him a cancer diagnosis and side effects he never needed. This is called overdiagnosis.
The traditional biopsy method adds to the problem. A biopsy takes small tissue samples with a needle, guided by ultrasound. The traditional approach, called systematic biopsy, samples multiple areas across the gland. That thoroughness is exactly why it keeps turning up small, low-grade tumors that no scan had flagged.
A Swedish trial invited more than 37,000 men to test a different sequence. First a PSA blood test. Then, for men whose PSA met the threshold, an MRI scan. Then a biopsy aimed only at suspicious spots the scan found.
Among the men who went through it, that approach sharply reduced the number of biopsies and cut low-grade cancer diagnoses roughly in half.
There is a tradeoff, and you should know it. Aiming only at what the MRI sees can miss or delay some cancers that matter, which systematic sampling would have caught. MRI improved the process. It did not make it perfect.
What to do about an elevated PSA
This is the part where general advice can do real harm, so read it carefully.
A single high PSA reading does not mean cancer, and it does not mean you need a biopsy tomorrow. PSA rises for several reasons that have nothing to do with cancer, and it often comes back down on a second test. Urology guidelines advise repeating a newly elevated PSA before ordering any further test.
From there, several tools can help work out whether a biopsy is warranted. These include validated risk calculators, additional blood or urine tests, and prostate MRI. Which ones make sense depends on your overall risk.
Two cautions matter here.
MRI is not a perfect gatekeeper. An MRI that shows no suspicious spot does not always mean you are in the clear. Some men remain at high enough risk that a systematic biopsy is still the right call. Do not conclude that a biopsy was improper simply because no MRI came first.
And be careful with the idea that a rising PSA is what counts. Earlier readings give useful context, but urology guidelines specifically advise against using the rate of change on its own to justify further testing or a biopsy. A newly high reading needs confirming first.
When to start
Guidelines disagree here, and you deserve to know that rather than being handed false certainty.
The U.S. Preventive Services Task Force, which advises on screening nationally, last issued guidance in 2018. It says men aged 55 to 69 should make an individual decision after discussing benefits and harms with a clinician. It recommends against routine PSA screening at 70 and older. The Task Force began work on an update in 2023, and that update has not yet been published. It also acknowledged it did not have enough evidence to write separate recommendations for Black men and men with family histories, despite their higher risk.
The American Cancer Society sets the conversation earlier and sorts it by risk:
Age 50 for men at average risk who are expected to live at least 10 more years.
Age 45 for Black men, and for men with a father or brother diagnosed before 65.
Age 40 for men with more than one close relative diagnosed young.
Urology guidance goes further. The American Urological Association and the Society of Urologic Oncology recommend offering screening from age 40 to 45 for men at increased risk, which they define as Black ancestry, an inherited gene change, or a strong family history. For everyone else they suggest a baseline PSA somewhere between 45 and 50, then regular screening every two to four years from 50 to 69.
The right starting age and testing interval depend on how strong your particular risk is, which is why this is a conversation rather than a fixed rule.
Your plan
Know your risk in your forties. Learn whether close relatives had prostate cancer, especially young. Look for a family pattern of prostate, breast, ovarian, pancreatic, colon, or uterine cancer, particularly several relatives or unusually young diagnoses. Ask about genetic counseling if that pattern is there.
Start the conversation earlier if you are at higher risk. Between 40 and 45 if you are Black, have a strong family history, or carry a relevant inherited gene change. Around 50 if you are at average risk. These are discussions, not automatic tests.
If a PSA comes back high, do not panic and do not rush. Ask about repeating it. Ask what your overall risk looks like, and whether a risk calculator, an additional test, or an MRI would help decide about biopsy.
Understand MRI's limits. It can spare you an unnecessary biopsy. It cannot rule out every serious cancer.
If you are diagnosed with low-risk disease, ask about active surveillance. This is not a fringe option. Urology and radiation oncology guidelines name active surveillance as the preferred management for low-risk prostate cancer, on their strongest level of evidence. It means monitoring closely instead of treating right away, which avoids or delays the urinary and sexual side effects of treatment while keeping the option to treat if anything changes.
Protect your overall health. Do not smoke. Exercise. Keep a healthy weight. Eat well. Do not take high-dose vitamin E or selenium hoping to prevent prostate cancer.
The bottom line
No food, supplement, drug, or lifestyle plan has been proven to reliably prevent lethal prostate cancer. High-dose vitamin E and selenium should not be used to try. Not smoking has the clearest link to lower prostate cancer death of anything on the modifiable list. The other habits worth keeping are worth keeping for well-established reasons, and they may also go along with better prostate outcomes, but that evidence is observational.
For men who choose screening, the goal is not to find more cancer. It is to catch the serious kind early while avoiding unnecessary biopsies and unnecessary treatment. That means weighing your age, ancestry, family history, and inherited risk, confirming a high PSA before acting on it, and using the newer tools where they help.
That is the honest offer. Not guaranteed prevention, and not risk-free detection. A modest but real reduction in the odds of dying from this disease, with tradeoffs you should understand before you begin.
Proactive Health Labs publishes evidence-based health literacy resources. This article summarizes published research and is not individual medical advice. Talk with your own clinician about decisions that affect you.
Sources
Bell KJL, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137(7):1749–1757. https://pmc.ncbi.nlm.nih.gov/articles/PMC4682465/
Kratzer TB, Mazzitelli N, Star J, et al. Prostate cancer statistics, 2025. CA Cancer J Clin. 2025. doi:10.3322/caac.70028. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.70028
National Cancer Institute. Genetics of Prostate Cancer (PDQ), Health Professional Version. https://www.cancer.gov/publications/pdq/information-summaries/genetics
Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers (SELECT). JAMA. 2009;301(1):39–51.
Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: SELECT. JAMA. 2011;306(14):1549–1556. https://jamanetwork.com/journals/jama/fullarticle/1104493
National Cancer Institute. SELECT Trial Results Q&A. https://www.cancer.gov/types/prostate/research/select-trial-results-qa
Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014. https://pubmed.ncbi.nlm.nih.gov/25242554/
Al-Fayez S, El-Metwally A. Cigarette smoking and prostate cancer: a systematic review and meta-analysis of prospective cohort studies. Tob Induc Dis. 2023;21:19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900478/
Bañez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298(19):2275–2280. https://jamanetwork.com/journals/jama/fullarticle/209508
Grubb RL 3rd, Black A, Izmirlian G, et al. Serum PSA hemodilution among obese men undergoing screening in the PLCO Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009;18:748–751. https://pubmed.ncbi.nlm.nih.gov/19258472/
Vidal AC, Howard LE, Sun SX, et al. Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. https://pmc.ncbi.nlm.nih.gov/articles/PMC4257871/
Perez-Cornago A, Appleby PN, Pischon T, et al. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med. 2017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508687/
Dickerman BA, Torfadottir JE, Valdimarsdottir UA, et al. Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study. Cancer. 2019;125:2877–2885. doi:10.1002/cncr.32167
World Cancer Research Fund / AICR. Continuous Update Project: Diet, Nutrition, Physical Activity and Prostate Cancer. 2014. https://www.wcrf.org/wp-content/uploads/2024/10/prostate-cancer-report.pdf
López-Solís R, et al. Lycopene intake and prostate cancer risk in men at high cardiovascular risk: a prospective cohort study. BMC Med. 2025. https://link.springer.com/article/10.1186/s12916-025-04440-0
Markozannes G, Tzoulaki I, Karli D, et al. Diet, body size, physical activity and risk of prostate cancer: an umbrella review of the evidence. Eur J Cancer. 2016;69:61–69. doi:10.1016/j.ejca.2016.09.026
Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224.
Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the Prostate Cancer Prevention Trial. N Engl J Med. 2013;369:603–610. https://pubmed.ncbi.nlm.nih.gov/23944298/
Goodman PJ, Tangen CM, Darke AK, et al. Long-term effects of finasteride on prostate cancer mortality. N Engl J Med. 2019;380(4):393–394. https://www.nejm.org/doi/full/10.1056/NEJMc1809961
Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer (REDUCE). N Engl J Med. 2010;362:1192–1202.
Roobol MJ, et al. European Study of Prostate Cancer Screening: 23-year follow-up. N Engl J Med. 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2503223
Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592–599. https://pmc.ncbi.nlm.nih.gov/articles/PMC5725951
Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized PLCO Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–132.
Hugosson J, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only (GÖTEBORG-2). N Engl J Med. 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2209454
Hugosson J, et al. Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med. 2024;391:1083–1095.
U.S. Preventive Services Task Force. Screening for prostate cancer: recommendation statement. JAMA. 2018;319(18):1901–1913. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
U.S. Preventive Services Task Force. Final research plan: prostate cancer screening. 2023. https://www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/prostate-cancer-screening-adults
American Cancer Society. American Cancer Society Recommendations for Prostate Cancer Early Detection. https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html
Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline (2026). American Urological Association. doi:10.1097/JU.0000000000004995. https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guideline
Eastham JA, Auffenberg GB, Barocas DA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2026 Amendment). American Urological Association. doi:10.1097/JU.0000000000005060. https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer